Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07575906 | A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults. | PHASE1 | RECRUITING | 8 | — | — | May 8, 2026 | Jul 23, 2026 | May 28, 2026 | 1 | United States |
Assessment of TEAEs, SAEs, clinical laboratory values, vital signs, continuous cardiac monitoring and 12-lead ECGs
| Arm | Type | Description |
|---|---|---|
| PF-08057418 | EXPERIMENTAL | Participants will receive single oral solution or tablet dose(s) of PF-08057418 |
| Placebo | PLACEBO_COMPARATOR | Participants will receive single oral solution or tablet dose(s) of placebo. |
| Name | Type | Description |
|---|---|---|
| PF-08057418 | DRUG | solution or tablet (fasted/fed) |
| Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.) | OTHER | solution or tablet (fasted/fed) |
Inclusion Criteria: * Adults 18 to 60 years of age (or the minimum age of consent per local regulations) at screening. * Healthy participants, as determined by medical history, physical examination, clinical laboratory tests, and cardiac monitoring. * Body mass index (BMI) between 16 and 32 kg/m² a...